The analyses of biopsies showed that JAK1/2 truncating mutations resulted in loss of PD-L1 expression and changed the molecular profile of the melanoma.141, 142 Overall, although immunotherapy has become a promising and unique strategy for cancer treatment, an integrative strategy should be prepared to prevent drug resistance. This evidence concerns the gene JAK1 and melanoma.